Cargando…

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 (IDH1(mut)), present in 7–14% of AML patients, have been discovered recently, opening the door to targeted agents aiming to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Megías-Vericat, Juan Eduardo, Ballesta-López, Octavio, Barragán, Eva, Montesinos, Pau
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663038/ https://www.ncbi.nlm.nih.gov/pubmed/31413655 http://dx.doi.org/10.2147/BLCTT.S177913

Ejemplares similares

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
por: de Botton, Stéphane, et al.
Publicado: (2023)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
por: de Botton, Stéphane, et al.
Publicado: (2023)

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
por: Megías-Vericat, Juan Eduardo, et al.
Publicado: (2022)

Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies
por: Madala, Hanumantha Rao, et al.
Publicado: (2018)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Extracorporeal photopheresis vs standard therapies for steroid‐refractory chronic graft‐vs‐host disease: Pharmacoeconomic assessment of hospital resource use in Spain
por: Boluda, Blanca, et al.
Publicado: (2021)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
por: Bill, Marius, et al.
Publicado: (2022)

IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics
por: ElNahass, Yasser H, et al.
Publicado: (2020)

Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML
por: Wang, JingHan, et al.
Publicado: (2020)

IDH1 as a Cooperating Mutation in AML Arising in the Context of Shwachman-Diamond Syndrome
por: Mourad, Stéphanie, et al.
Publicado: (2019)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

PB1783: IDENTIFICATION OF RAMAN SPECTROSCOPIC SIGNATURE OF IDH MUTATIONS IN AML IN VITRO MODEL
por: Laskowska, P., et al.
Publicado: (2022)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Relapsed or primary refractory AML: moving past MEC and FLAG-ida
por: Koenig, Kristin, et al.
Publicado: (2020)

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
por: Gionfriddo, Ilaria, et al.
Publicado: (2021)

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
por: Smith, Catherine C., et al.
Publicado: (2022)

Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells
por: Palau, Anna, et al.
Publicado: (2023)

Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy
por: Nassereddine, Samah, et al.
Publicado: (2018)

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
por: Klement, Piroska, et al.
Publicado: (2022)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
por: Mondesir, Johanna, et al.
Publicado: (2016)

Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
por: Solana-Altabella, Antonio, et al.
Publicado: (2022)

Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects
por: Lam, Marissa, et al.
Publicado: (2020)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
por: Thumallapally, Nishitha, et al.
Publicado: (2016)

Current status and future perspectives in targeted therapy of NPM1-mutated AML
por: Ranieri, Roberta, et al.
Publicado: (2022)

Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR(TM) In Patients With AML And Their Clinical Impact In Mexico City
por: Olarte, Irma, et al.
Publicado: (2019)

IDH1-R132 changes vary according to NPM1 and other mutations status in AML
por: Falini, Brunangelo, et al.
Publicado: (2019)

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
por: Messina, Monica, et al.
Publicado: (2022)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
por: Arnan, Montserrat, et al.
Publicado: (2023)

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
por: Libura, Marta, et al.
Publicado: (2021)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
por: Hammond, Danielle, et al.
Publicado: (2023)

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME
por: Dinardo, Courtney, et al.
Publicado: (2023)

P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.
por: Bhide, Aniket, et al.
Publicado: (2023)

Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
por: Lessi, Federica, et al.
Publicado: (2021)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

Refractory relapsing polychondritis: challenges and solutions
por: Lekpa, Fernando Kemta, et al.
Publicado: (2018)

Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells
por: Wilson, Elisabeth R., et al.
Publicado: (2021)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
por: Cortes, Jorge, et al.
Publicado: (2023)

Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients
por: Wang, Jing-Han, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jfi7dcplrpc0h12q3h3qc66lv0